DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

0.00 0.00 (0.00%)

Quote as of


company name or ticker

Recent Quotes

CADX 0.00 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open 0.00
Previous Close 0.00
Daily Range 0.00 - 0.00
52-Week Range 0.00 - 0.00
Market Cap 0.0000
P/E Ratio 0.00
Dividend (Yield) 0.00 (0.0%)
Volume 0
Average Daily Volume 0
Current FY EPS 0.13

Sector

Healthcare

Industry

Drug Makers

Cadence Pharmaceuticals, Inc. (CADX) Description

A biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. Website: http://www.cadencepharm.com/

News & Commentary

Mallinckrodt plc Takes a Big Swing for Growth

In buying Questcor, Mallinckrodt is acquiring exceptional potential for earnings, controversy, and disappointment

Can Malllinckrodt Keep on Crushing Expectations?

FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog

Recro Pharma IPO Could Be More Painful Than Expected

Wider-Than-Expected Q4 Loss at Cadence Pharma - Analyst Blog

Wider-Than-Expected Q4 Loss at Cadence Pharma - Analyst Blog

Patent Update from Mallinckrodt - Analyst Blog

Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog

This Week in Biotech: Three Strikes and You're Out!

The FDA and its advisory panel give a thumbs down to three experimental drugs, while buyout mania strikes the biotech sector.

Cadence: What To Do With The Proceeds And A Post Mortem On A Successful Investment

Everyone Wins in This Big Pharma Buyout

Here's one pharmaceutical buyout that the market loved on all sides.

See More CADX News...

CADX's Top Competitors

CADX 0.00 (0.00%)
Current stock: CADX
JNJ $101.08 (0.62%)
Current stock: JNJ
NVS $104.28 (-1.16%)
Current stock: NVS
PFE $35.27 (-0.25%)
Current stock: PFE